Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Provided By GlobeNewswire
Last update: Jan 13, 2025
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically-validated therapies for neurodegeneration
Read more at globenewswire.com
